683 Capital Management, LLC and Related Parties Report 5.36% Ownership in Reviva Pharmaceuticals Holdings, Inc.

683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have jointly filed a Schedule 13G with the SEC, reporting a 5.36% ownership in Reviva Pharmaceuticals Holdings, Inc. as of September 29, 2025. The filing indicates that 683 Capital Partners, LP beneficially owns 450,000 shares of Common Stock and warrants to purchase 4,985,000 shares of Common Stock, which are currently exercisable. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, and Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficial ownership of these shares. The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended.